

Clear cell sugar tumour – A rare lung tumour

João Paulo Duarte dos Santos Oliveira Rodrigues*, Mário Pinto, Miguel Cristóvão, Rita Gerardo

Centro Hospitalar e Universitário Lisboa Central, Portugal.

Received Date : July 26, 2023
Accepted Date : September 07, 2023
Published Date : September 14, 2023
Archived : www.jcmimagescasereports.org
Copyright : © João Paulo Duarte dos Santos Oliveira Rodrigues 2023

***Corresponding Author:** João Paulo Duarte dos Santos Oliveira Rodrigues, Hospital de Santa Marta - Centro Hospitalar e Universitário Lisboa Central, Portugal.
 Email: joao.oliveira.rodrigues.pneumo@gmail.com

Clinical Image

A 82-year-old woman, never smoker, retired farmer with known medical history of hypertension, heart failure, chronic kidney disease, hyperuricemia, and dyslipidaemia was referred to a pulmonology consultation due to the identification of a nodule on a chest-x-ray and one-year history of fatigue. A chest computed tomography (CT) scan confirmed a well-defined nodular lesion (22x20mm) in the external segmental of the middle lobe. A positron emission tomography and computed tomography (PET) scan showed increased metabolic activity (SUVMax of 3.5). A transthoracic biopsy identified epithelioid cells with a clear cytoplasm, and immunohistochemical positivity for HMB45 and Melan A confirming a lung clear cell sugar tumour Clear Cell Sugar Tumour. In the multi-disciplinary discussion of thoracic oncology it was decided to proceed with imaging surveillance due to the presence of significant comorbidities and the typically indolent behaviour of the tumour. Patient underwent semi-annual imaging reevaluations that did not show any tomographic changes.




Figure 1: September 2020- well defined nodule in the middle lobe.




Figure 2: PET scan identifying a SUVMax 3,5.

Citation: João Paulo Duarte dos Santos Oliveira Rodrigues. Clear cell sugar tumour – A rare lung tumour. J Clin Med Img Case Rep. 2023; 3(5): 1547.




Figure 3: Panel A: Clear cells under hematoxylin and eosin staining. Panel B: positivity for HMB 45.




Figure 4: December 2021-stable disease.




Figure 5: August 2022- stable disease.